CONTINUUS awarded SBIR Phase II grant from the NSF

CONTINUUS Pharmaceuticals was awarded a Phase II SBIR grant from the National Science Foundation to further develop its breakthrough ICM technology. This Phase II grant consists of $750,000 over a two year period, with the opportunity for additional matching funds to facilitate commercial partnerships.

Comments are closed.